Oncologic Safety and Recurrence Patterns of Watchful Waiting After Neoadjuvant Therapy for Esophageal Cancer

Clicks: 27
ID: 315791
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #248 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Esophagectomy remains a cornerstone of curative treatment for esophageal cancer but is associated with substantial morbidity and mortality, particularly in elderly and comorbid patients. As an alternative, watchful waiting (WW)—omitting surgery in patients with a clinical complete response after neoadjuvant therapy and reserving esophagectomy for recurrence—has gained increasing attention. However, WW carries the risk of missing a curative window and allowing progression to metastatic disease, making careful patient selection essential. Aims To analyze recurrence patterns in patients managed with a WW strategy. Methods We retrospectively analyzed all patients undergoing curative-intent treatment for esophageal cancer at our institution between 2014 and 2022. Follow-up data were reviewed until 2025 to ensure a minimum follow-up of at least two years for all patients. Results Among 458 patients with esophageal cancer treated with neoadjuvant chemoradiotherapy, 50 patients were managed with a WW approach. Of these, 8 patients (16%) initially presented with local tumor regrowth without lymph node involvement, while 39 patients (79%) had evidence of regional lymph node involvement. Overall, 30 patients (60%) developed disease recurrence during follow-up. Of these, 15 patients (50%) experienced local or regional recurrence that remained potentially amenable to curative treatment, 10 patients (33%) developed distant metastatic disease, and 5 patients (17%) declined further diagnostic evaluation. Notably, patients with initially localized tumor regrowth without lymph node involvement did not develop distant metastases (Figure 1). Conclusion These findings suggest that a watchful waiting strategy may be safe in carefully selected patients without regional lymph node involvement, for whom follow-up can primarily focus on endoscopic surveillance. In contrast, patients with regional disease may still be considered for WW; however, follow-up should be intensified and include regular imaging to enable early detection of distant metastases.Figure 1:Patterns of recurrence in patients managed with a watchful waiting strategyFor image description, please refer to the figure legend and surrounding text.
Reference Key
openalex_W7163325128 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag055.066
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.